We use cookies for a better user experience. Read our Privacy Policy

I Agree

Acute Viral Rhinosinusitis Treatment Market Trends, 2021-2031

Acute Viral Rhinosinusitis Treatment Market (Treatment: Saline Nasal Spray, Nasal Corticosteroids, Decongestants, NSAIDs, and Others; Route of Administration: Topical, Nasal, Oral, and Injectable; Distribution Channel: Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies; and Infection Type: Rhinovirus [Picornavirus] and Non-Rhinovirus) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Dupilumab Being Publicized for CRSwNP Treatment in COVID-19 Patients

An increasing number of patients suffering from severe chronic rhinosinusitis with nasal polyps (CRSwNP) is being exposed to COVID-19. In order to improve patient outcomes in these individuals, companies in the acute viral rhinosinusitis treatment market are increasing their output capacities in dupilumab. Dupilumab is associated with improvement in sinonasal function, which is essential for initially tackling coronavirus.

Dupilumab helps to improve nasal symptoms such as congestion, thus positively affecting the upper respiratory tract. Manufacturers in the acute viral rhinosinusitis treatment market are boosting their production capabilities for other treatments such as nasal corticosteroids and decongestants apart from dupilumab to reduce morbidity and mortality rates amid the ongoing pandemic. The completion of the treatment with dupilumab is recommended, since interruption in the therapy could lead to the progression of rhinosinusitis and worsening of common comorbidities including asthma.

To know the scope of our report Get a Sample on Acute Viral Rhinosinusitis Treatment Market

Individual Consideration for Medicines Reduce Complications of ARS

The acute viral rhinosinusitis treatment market is projected to surpass US$ 3.16 Bn by 2031. However, it has been found that in many cases, antibiotics do not prevent the complications of bacterial acute rhinosinusitis (ABRS). This has led to the growing awareness about individual considerations, and taking into account the adverse effects and drug resistances before prescribing antibiotics.

On the other hand, individualized use of intranasal corticoids has proven to be useful in post-vital acute rhinosinusitis (ARS). Manufacturers are bolstering their production capabilities in over-the-counter analgesics and saline nasal irrigation for the treatment of ARS.

Get a glimpse of the in-depth analysis through our Report Brochure

Amoxicillin, Clavulanate Being Recommended to Patients at Risk of Pneumococcal Resistance

Companies in the acute viral rhinosinusitis treatment market are increasing the availability of amoxicillin and clavulanate as a means of appropriate initial therapy for ABRS patients who do not have risk factors for resistance. The combination of amoxicillin and clavulanate is prescribed for children compared to adults. However, there is an increasing emergence of antimicrobial resistance among respiratory pathogens. Hence, manufacturers in the acute viral rhinosinusitis treatment market are increasing their R&D for routine conjugated pneumococcal vaccination in children, which has changed the spectrum of bacterial infection.

The high dose of amoxicillin and clavulanate is being recommended for patients at high risk of pneumococcal resistance. The increasing microbial resistance to antibiotics is leading to the popularity of either amoxicillin or amoxicillin-clavulanate for the treatment of ABRS.

Topical Corticosteroid Nasal Sprays Relieve Congestion in Patients

Nasal saline irrigation is found to effectively remove or reduce the burden of debris and pathogens locally from the nares, resulting in symptomatic relief. Companies in the acute viral rhinosinusitis treatment market are increasing their output capacities in topical intranasal therapies to reduce congestion in patients. Topical corticosteroid nasal sprays help to reduce mucosal inflammation, thus reducing stenosis of the sinus drainage pathways. As such, nasal corticosteroids are expected to dominate the second highest revenue among all treatment types in the acute viral rhinosinusitis treatment market.

On the other hand, topical antihistamine can help lower inflammation and irritation of the mucosa, while reducing edema in the nasal passages and opening up the sinus ostia.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Apart from boosting production of dupilumab and other medications, special epidemic situations such as the ongoing coronavirus pandemic are requiring strict recommendations including social distancing and home confinement. The acute viral rhinosinusitis treatment market is projected to grow at a CAGR of 5.3% during the forecast period. This is evident since the economic burden of ARS is incredibly high, owing to a large number of medical visits. Moreover, misuse of diagnostic testing and overuse of medications lead to high indirect costs. Hence, stakeholders and healthcare providers need to create awareness that ARS is a self-resolving and mild disease that can be treated with the help of individual consideration for medicines.

Acute Viral Rhinosinusitis Treatment Market: Overview

  • The term acute rhinosinusitis (ARS) refers to symptomatic inflammation of the nasal cavity and paranasal sinuses that lasts less than four weeks, a viral infection is the most prevalent cause of acute viral rhinosinusitis
  • Acute bacterial rhinosinusitis (ABRS) is a nasal and sinus infection. The air-filled space behind the nose is called the nasal cavity. The sinuses are a collection of spaces created by facial bones. These attach to the inside of the nose.
  • The global acute viral rhinosinusitis treatment market is anticipated to be driven by the increase in rhinosinusitis patients. In 2018, the CDC estimated that 28.9 million individuals in the U.S. were diagnosed with rhinosinusitis.
  • Increase in incidence of mucosal inflammation leading to rhinosinusitis is expected to drive the global market over the next few years
  • Demand for acute viral rhinosinusitis treatment is likely to increase due to rise in awareness about sinusitis treatment. New product and device development in the field of acute viral rhinosinusitis treatment is projected to boost the growth of the global market.

Increase in Product Launches and Approvals

  • The global acute viral rhinosinusitis treatment market is anticipated to be driven by increase in product approvals over the next few years. In December 2020, AstraZeneca announced that it has received marketing authorization from the Drugs Controller General of India (DCGI) for Fasenra. In individuals with severe asthma (eosinophilic asthma) or chronic rhinosinusitis, Fasenra is used in the injection form in a single dose prefilled syringe subcutaneous administration alone. Adult patients with severe asthma with an eosinophilic phenotype or patients with chronic rhinosinusitis are prescribed benralizumab (Fasenra) as an add-on maintenance therapy.

Market Segmentation: Acute Viral Rhinosinusitis Treatment Market

  • In terms of treatment, the global acute viral rhinosinusitis treatment market has been classified into saline nasal spray, nasal corticosteroids, decongestants, NSAIDS, and others
  • Based on route of administration, the global acute viral rhinosinusitis treatment market has been categorized into topical, nasal, oral, and injectable
  • In terms of distribution channel, the global acute viral rhinosinusitis treatment market has been segregated into online pharmacies, retail pharmacies, and hospital pharmacies
  • Based on infection type, the global acute viral rhinosinusitis treatment market has been divided into rhinovirus (picornavirus) and non-rhinovirus
  • Each of the segments has been analyzed in detail for acute viral rhinosinusitis treatment trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The acute viral rhinosinusitis treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Acute Viral Rhinosinusitis Treatment Market

  • The global acute viral rhinosinusitis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America accounted for the largest share of the global acute viral rhinosinusitis treatment market in 2020 and the trend is expected to continue during the forecast period. Growth of the acute viral rhinosinusitis treatment market in North America can be primarily ascribed to rise in cases of rhinosinusitis in the U.S. For instance, rhinosinusitis accounted for around 12 million to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the growth of the global acute viral rhinosinusitis treatment market.
  • Asia Pacific is anticipated to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are expected to drive the acute viral rhinosinusitis treatment market in the region over the next few years. Surge in healthcare expenditure and rise in awareness about sinusitis are likely to propel the market in the region.
  • The demand for acute viral rhinosinusitis treatment is also driven by the launch of acute viral rhinosinusitis treatment products by major companies in the region. On December 22, 2020, AstraZeneca announced marketing authorization from the Drugs Controller General of India (DCGI) for usage of Fasenra (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml subcutaneous administration only) in patients with severe asthma (eosinophilic asthma) or chronic rhinosinusitis. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients or patients with chronic rhinosinusitis.
  • The current and future market sizes in terms of value (US$ Mn) of the regional markets and major countries have been provided in the report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global acute viral rhinosinusitis treatment market
  • Leading players analyzed in the report are
    • Sun Pharmaceutical Industries, Inc.
    • Pfizer, Inc.
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Fresenius Kabi USA, LLC
    • Dr. Reddy's Laboratories, Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Abbott Laboratories
    • Bayer AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb
    • Merck & Co, Inc.
    • AstraZeneca plc
    • Amneal Pharmaceuticals LLC
    • GlaxoSmithKline plc
    • Aurobindo Pharma
    • Hikma Pharmaceuticals plc
    • Wockhardt
    • Mylan N.V.
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Acute Viral Rhinosinusitis Treatment Market – Segmentation

TMR’s study on the global acute viral rhinosinusitis treatment market includes information divided into four segments: treatment, route of administration, distribution channel, infection type, and region.

Treatment
  • Saline Nasal Spray
  • Nasal Corticosteroids
  • Decongestants
  • NSAIDs
  • Others
Route of Administration
  • Topical
  • Nasal
  • Oral
  • Injectable
Distribution Channel
  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies
Infection Type
  • Rhinovirus (Picornavirus)
  • Non-Rhinovirus
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Changing industry trends and other crucial market dynamics associated with these segments of the global acute viral rhinosinusitis treatment market have been discussed in detail.

Acute Viral Rhinosinusitis Treatment Market Trends, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of acute viral rhinosinusitis treatment market?

Acute viral rhinosinusitis treatment market is projected to surpass US$ 3.16 Bn by 2031

What is the anticipated CAGR of the acute viral rhinosinusitis treatment market in the forecast period?

Acute viral rhinosinusitis treatment market is projected to expand at a CAGR of 5.3% from 2021 to 2031

What are the key driving factors for the growth of the acute viral rhinosinusitis treatment market?

Acute viral rhinosinusitis treatment market is driven by increase in incidence of mucosal inflammation leading to rhinosinusitis

Which region is expected to project the highest market share in the global acute viral rhinosinusitis treatment market?

North America dominated the global acute viral rhinosinusitis treatment market in 2020, and the trend is anticipated to continue during the forecast period.

Who are the key players in the global acute viral rhinosinusitis treatment market?

Key players in the global acute viral rhinosinusitis treatment market include Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Viral Rhinosinusitis Treatment Market

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

    4.3. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, 2017–2031

5. Market Outlook

    5.1. Clinical Trials & Regulatory Approvals Analysis

    5.2. List of Brand / Product Approved

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    5.4. Technological Advancements

    5.5. Disease Prevalence & Incidence

6. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Treatment

    6.1. Introduction & Definition

    6.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031 

        6.2.1. Saline Nasal Spray

        6.2.2. Nasal Corticosteroids

            6.2.2.1. Fluticasone

            6.2.2.2. Budesonide

            6.2.2.3. Mometasone

            6.2.2.4. Others

        6.2.3. Decongestants

            6.2.3.1. Topical Decongestants

            6.2.3.2. Systemic Decongestants

        6.2.4. NSAIDs

            6.2.4.1. Acetaminophen

            6.2.4.2. Ibuprofen

            6.2.4.3. Aspirin

            6.2.4.4. Others

    6.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration

7. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

        7.2.1. Acute Viral Rhinosinusitis Treatment

            7.2.1.1. Topical

            7.2.1.2. Nasal

            7.2.1.3. Oral

            7.2.1.4. Injectable

    7.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration

8. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        8.2.1. Acute Viral Rhinosinusitis Treatment

            8.2.1.1. Online Pharmacies

            8.2.1.2. Retail Pharmacies

            8.2.1.3. Hospital Pharmacies

    8.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Infection Type

    9.1. Introduction & Definition

    9.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        9.2.1. Rhinovirus (Picornavirus)

        9.2.2. Non-Rhinovirus 

            9.2.2.1. Influenza

            9.2.2.2. Enterovirus

            9.2.2.3. Adenovirus

            9.2.2.4. Others

    9.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Infection Type

10. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Region

11. North America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

    11.1. Introduction

    11.2. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        11.2.1. Saline Nasal Spray

        11.2.2. Nasal Corticosteroids

            11.2.2.1. Fluticasone

            11.2.2.2. Budesonide

            11.2.2.3. Mometasone

            11.2.2.4. Others

        11.2.3. Decongestants

            11.2.3.1. Topical Decongestants

            11.2.3.2. Systemic Decongestants

        11.2.4. NSAIDs

            11.2.4.1. Acetaminophen

            11.2.4.2. Ibuprofen

            11.2.4.3. Aspirin

            11.2.4.4. Others

        11.2.5. Others

    11.3. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

        11.3.1. Acute Viral Rhinosinusitis Treatment

            11.3.1.1. Topical

            11.3.1.2. Nasal

            11.3.1.3. Oral

            11.3.1.4. Injectable

    11.4. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        11.4.1. Acute Viral Rhinosinusitis Treatment

            11.4.1.1. Online Pharmacies

            11.4.1.2. Retail Pharmacies

            11.4.1.3. Hospital Pharmacies

    11.5. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        11.5.1. Rhinovirus (Picornavirus)

        11.5.2. Non-Rhinovirus

            11.5.2.1. Influenza

            11.5.2.2. Enterovirus

            11.5.2.3. Adenovirus

            11.5.2.4. Others

    11.6. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis

        11.7.1. By Treatment

        11.7.2. By Route of Administration

        11.7.3. By Distribution Channel

        11.7.4. Infection Type

        11.7.5. By Country

12. Europe Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        12.2.1. Saline Nasal Spray

        12.2.2. Nasal Corticosteroids

            12.2.2.1. Fluticasone

            12.2.2.2. Budesonide

            12.2.2.3. Mometasone

            12.2.2.4. Others

        12.2.3. Decongestants

            12.2.3.1. Topical Decongestants

            12.2.3.2. Systemic Decongestants

        12.2.4. NSAIDs

            12.2.4.1. Acetaminophen

            12.2.4.2. Ibuprofen

            12.2.4.3. Aspirin

            12.2.4.4. Others

        12.2.5. Others

    12.3. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            12.3.1.1. Topical

            12.3.1.2. Nasal

            12.3.1.3. Oral

            12.3.1.4. Injectable

    12.4. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            12.4.1.1. Online Pharmacies

            12.4.1.2. Retail Pharmacies

            12.4.1.3. Hospital Pharmacies

    12.5. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        12.5.1. Rhinovirus (Picornavirus)

        12.5.2. Non-Rhinovirus

            12.5.2.1. Influenza

            12.5.2.2. Enterovirus

            12.5.2.3. Adenovirus

            12.5.2.4. Others

    12.6. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis

        12.7.1. By Treatment

        12.7.2. By Route of Administration

        12.7.3. By Distribution Channel

        12.7.4. By Infection Type

        12.7.5. By Country/Sub-region

13. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

    13.1. Introduction

    13.2. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        13.2.1. Saline Nasal Spray

        13.2.2. Nasal Corticosteroids

            13.2.2.1. Fluticasone

            13.2.2.2. Budesonide

            13.2.2.3. Mometasone

            13.2.2.4. Others

        13.2.3. Decongestants

            13.2.3.1. Topical Decongestants

            13.2.3.2. Systemic Decongestants

        13.2.4. NSAIDs

            13.2.4.1. Acetaminophen

            13.2.4.2. Ibuprofen

            13.2.4.3. Aspirin

            13.2.4.4. Others

        13.2.5. Others

    13.3. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            13.3.1.1. Topical

            13.3.1.2. Nasal

            13.3.1.3. Oral

            13.3.1.4. Injectable

    13.4. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            13.4.1.1. Online Pharmacies

            13.4.1.2. Retail Pharmacies

            13.4.1.3. Hospital Pharmacies

    13.5. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        13.5.1. Rhinovirus (Picornavirus)

        13.5.2. Non-Rhinovirus

            13.5.2.1. Influenza

            13.5.2.2. Enterovirus

            13.5.2.3. Adenovirus

            13.5.2.4. Others

    13.6. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis

        13.7.1. By Treatment

        13.7.2. By Route of Administration

        13.7.3. By Distribution Channel

        13.7.4. Infection Type

        13.7.5. By Country/Sub-region

14. Latin America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

    14.1. Introduction

    14.2. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        14.2.1. Saline Nasal Spray

        14.2.2. Nasal Corticosteroids

            14.2.2.1. Fluticasone

            14.2.2.2. Budesonide

            14.2.2.3. Mometasone

            14.2.2.4. Others

        14.2.3. Decongestants

            14.2.3.1. Topical Decongestants

            14.2.3.2. Systemic Decongestants

        14.2.4. NSAIDs

            14.2.4.1. Acetaminophen

            14.2.4.2. Ibuprofen

            14.2.4.3. Aspirin

            14.2.4.4. Others

        14.2.5. Others

    14.3. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            14.3.1.1. Topical

            14.3.1.2. Nasal

            14.3.1.3. Oral

            14.3.1.4. Injectable

    14.4. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

            14.4.1.1. Online Pharmacies

            14.4.1.2. Retail Pharmacies

            14.4.1.3. Hospital Pharmacies

    14.5. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        14.5.1. Rhinovirus (Picornavirus)

        14.5.2. Non-Rhinovirus

            14.5.2.1. Influenza

            14.5.2.2. Enterovirus

            14.5.2.3. Adenovirus

            14.5.2.4. Others

    14.6. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis

        14.7.1. By Treatment

        14.7.2. By Route of Administration

        14.7.3. By Distribution Channel

        14.7.4. Infection Type

        14.7.5. By Country/Sub-region

15. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

    15.1. Introduction

    15.2. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

        15.2.1. Saline Nasal Spray

        15.2.2. Nasal Corticosteroids

            15.2.2.1. Fluticasone

            15.2.2.2. Budesonide

            15.2.2.3. Mometasone

            15.2.2.4. Others

        15.2.3. Decongestants

            15.2.3.1. Topical Decongestants

            15.2.3.2. Systemic Decongestants

        15.2.4. NSAIDs

            15.2.4.1. Acetaminophen

            15.2.4.2. Ibuprofen

            15.2.4.3. Aspirin

            15.2.4.4. Others

        15.2.5. Others

    15.3. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

            15.3.1.1. Topical

            15.3.1.2. Nasal

            15.3.1.3. Oral

            15.3.1.4. Injectable

    15.4. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        15.4.1. Acute Viral Rhinosinusitis Treatment

            15.4.1.1. Online Pharmacies

            15.4.1.2. Retail Pharmacies

            15.4.1.3. Hospital Pharmacies

    15.5. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

        15.5.1. Rhinovirus (Picornavirus)

        15.5.2. Non-Rhinovirus

            15.5.2.1. Influenza

            15.5.2.2. Enterovirus

            15.5.2.3. Adenovirus

            15.5.2.4. Others

    15.6. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis

        15.7.1. By Treatment

        15.7.2. By Route of Administration

        15.7.3. By Distribution Channel

        15.7.4. By Infection Type

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Position Analysis, by Company, 2020

    16.2. Company Profiles

        16.2.1. Sun Pharmaceutical Industries, Inc.

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Growth Strategies

            16.2.1.3. SWOT Analysis

        16.2.2. Pfizer Inc.

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Growth Strategies

            16.2.2.3. SWOT Analysis

        16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Growth Strategies

            16.2.3.3. SWOT Analysis

        16.2.4. Fresenius Kabi USA, LLC.

            16.2.4.1. Company Overview (HQ, Business Segments)

            16.2.4.2. Growth Strategies

            16.2.4.3. SWOT Analysis

        16.2.5. Dr. Reddy's Laboratories, Inc.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Growth Strategies

            16.2.5.3. SWOT Analysis

        16.2.6. Novartis AG

            16.2.6.1. Company Overview (HQ, Business Segments)

            16.2.6.2. Growth Strategies

            16.2.6.3. SWOT Analysis

        16.2.7. Teva Pharmaceutical Industries Ltd.

            16.2.7.1. Company Overview (HQ, Business Segments)

            16.2.7.2. Growth Strategies

            16.2.7.3. SWOT Analysis

        16.2.8. Sanofi

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Growth Strategies

            16.2.8.3. SWOT Analysis

        16.2.9. Abbott Laboratories

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Growth Strategies

            16.2.9.3. SWOT Analysis

        16.2.10. Bayer AG

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Growth Strategies

            16.2.10.3. SWOT Analysis

        16.2.11. Eli Lilly And Company

            16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.11.2. Growth Strategies

            16.2.11.3. SWOT Analysis

        16.2.12. Bristol-Myers Squibb

            16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.12.2. Growth Strategies

            16.2.12.3. SWOT Analysis

        16.2.13. Merck & Co, Inc.

            16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.13.2. Growth Strategies

            16.2.13.3. SWOT Analysis

        16.2.14. AstraZeneca Plc

            16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.14.2. Growth Strategies

            16.2.14.3. SWOT Analysis

        16.2.15. Amneal Pharmaceuticals LLC

            16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.15.2. Growth Strategies

            16.2.15.3. SWOT Analysis

        16.2.16. GlaxoSmithKline plc

            16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.16.2. Growth Strategies

            16.2.16.3. SWOT Analysis

        16.2.17. Aurobindo Pharma

            16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.17.2. Growth Strategies

            16.2.17.3. SWOT Analysis

        16.2.18. Hikma Pharmaceuticals plc

            16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.18.2. Growth Strategies

            16.2.18.3. SWOT Analysis

        16.2.19. Wockhardt

            16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.19.2. Growth Strategies

            16.2.19.3. SWOT Analysis

        16.2.20. Mylan N.V.

            16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.20.2. Growth Strategies

            16.2.20.3. SWOT Analysis

List of Tables

Table 01: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 02: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031

Table 03: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031

Table 04: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031

Table 05: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 06: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 07: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 08: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031

Table 09: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 10: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 11: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 12: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031

Table 13: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031

Table 14: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031

Table 15: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 16: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 18: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031

Table 19: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 21: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031

Table 22: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031

Table 23: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031

Table 24: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 25: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 26: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 27: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031

Table 28: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 29: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 30: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031

Table 31: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031

Table 32: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031

Table 33: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 34: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 35: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 36: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031

Table 37: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 38: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 39: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031

Table 40: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031

Table 41: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031

Table 42: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 43: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 44: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 45: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031

Table 46: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 47: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 48: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031 

Table 49: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031

Table 50: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031

Table 51: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 52: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 53: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031

Table 54: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031

List of Figures

Figure 01: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 03: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 04: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Saline Nasal Spray, 2017-2031

Figure 05: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Nasal Corticosteroids, 2017-2031

Figure 06: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Decongestants, 2017-2031

Figure 07: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by NSAIDs, 2017-2031

Figure 08: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Others, 2017-2031

Figure 09: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 10: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 11: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Topical, 2017–2031

Figure 12: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Nasal, 2017–2031

Figure 13: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Oral, 2017–2031

Figure 14: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Injectable, 2017–2031

Figure 15: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031 

Figure 16: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 17: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Online Pharmacies, 2017-2031

Figure 18: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Retail Pharmacies, 2017-2031

Figure 19: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031

Figure 20: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 21: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 22: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Rhinovirus (Picornavirus), 2017–2031

Figure 23: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Non-rhinovirus, 2017–2031

Figure 24: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Region, 2020 and 2031

Figure 25: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Region, 2021–2031

Figure 26: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 27: North America Acute Viral Rhinosinusitis Market Value Share, by Country, 2020 and 2031

Figure 28: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country, 2021–2031

Figure 29: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 30: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 31: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 32: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 33: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 34: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 35: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 36: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 37: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 38: Europe Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 39: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 40: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 41: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 42: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 43: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 44: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 45: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 46: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 47: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 48: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 49: Asia Pacific Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 50: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 51: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 52: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 53: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 54: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 55: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 56: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 57: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 58: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 59: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 60: Latin America Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 61: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 62: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 63: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 64: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 65: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 66: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 67: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 68: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 69: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031

Figure 70: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 71: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 72: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 73: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031

Figure 74: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 75: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 76: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 77: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 78: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 79: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031

Figure 80: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

959

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved